DOPAMIN-D2-REZEPTOR-LIGANDEN
European patent · EP3233077 · In force
Register entry
- Publication number
- EP3233077
- Application number
- EP15871250
- Kind
- European patent with effect for Switzerland and Liechtenstein
- Status
- In force
- Specification
- Granted
- Filed
- Dec 18, 2015
- Published
- Oct 25, 2017
- Granted
- May 6, 2026
- Protection ends at the latest
- Dec 17, 2035
- Next annual fee due
- Dec 31, 2026
- IPC classes
- A61K 31/40 (2006.01)C07D 401/06 (2006.01)A61P 25/16 (2006.01)A61P 25/18 (2006.01)
- Priority
- US 201462094670 P 19.12.2014
- PCT application
- PCT/US2015/066928 18.12.2015
- PCT publication
- WO2016/100940 23.06.2016
- Filing language
- English
- Source
- Swissreg
History
What the Federal Institute of Intellectual Property published about this title, newest first.
- May 6, 2026
Granted
- Specification status
- Non-published patent application → Granted patent
- Status of protective title
- Initiated → Active
Published in Swissreg on 06.05.2026
Parties
Holder
Inventor
HOLSON, Edward
Newton, MA 02461, US
WAGNER, Florence, Fevrier
Ashland, MA 01721, US
WEIWER, Michel
Cambridge, MA 02141, US
SCOLNICK, Edward
Wayland, MA 01778, US
PALMER, Michelle
Harvard, MA 01451, US
DORDEVIC, Luka
34133 Trieste, IT
LEWIS, Michael
Dedham, MA 02026, US
PAN, Jennifer, Q.
Acton, MA 01720, US
ZHANG, Yan-Ling
Lexington, MA 02421, US
XU, Qihong
Newton, MA 02461, US
The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.